<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="lead">
            <roleset id="lead.01" name="resulted&#x0A;" wordnet="3">
                <roles>
                    <role n="0" descr="factors&#x0A;" />
                    <role n="2" descr="result&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>A0 (i. e., in turn, will lead to synergic activation of the ANA and other target promoters of MEF2 regardless of the meF2 DNA binding activity.</text>
                    <arg n="1">synergic activation of the ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 (i.e., in turn, led to synergic activation of the ANF and other MEF2 target promoters regardless of the binding activity of meF2.</text>
                    <arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0, in turn, is able to lead to synergic activation of the ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergic activation of the ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A0, in turn, is capable of leading to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A0, in turn, led to synergic activation of the ANA and other MEF2 target promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergic activation of the ANA and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0, in turn, led to synergic activation of the ANF and other MEF2 target promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A0, in turn, led to synergistic activation of ANA and other target MEF2 promoters regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target MEF2 promoters</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A0, in turn, will lead to synergistic activation of ANA and other target promoters of MEF2 regardless of the DNA binding activity of MEF2.</text>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>BRE identification is led to sequence selection experience.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>BRE identification was led by sequence selection experience.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>C2+e-mediated transcriptional supression was led by nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D has led in a 40 to 50-fold synergistic activation of the ANA promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the ANA promoter, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D was able to lead to a 40 to 50-fold synergistic activation of the ANA promoter when the cells were grown in rich environments.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Crl stimulates sigma (S) activity can lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Crl stimulates sigma (S) activity can lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Crl stimulates sigma (S) activity is able to lead an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase (picture 3A).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Crl stimulates sigma (S) activity leading to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Crl stimulates sigma (S) activity leading to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Crl stimulates sigma (S) activity leads to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Crl stimulates sigma activity (S) can lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase (figuration 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Crl stimulates sigma activity (S) can lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Crl stimulates sigma activity (S) can lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Crl stimulates sigma activity (S) can lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase (figuration 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Crl stimulates sigma activity (S) is leading to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Crl stimulates sigma activity (S) is leading to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Crl stimulates sigma activity (S) leading to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Crl stimulates sigma activity (S) leads to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>Crl stimulates sigma activity (S) led an increase in the transcription rate of a subset of rpoS genes in the stationary phase to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>Crl stimulates sigma activity (S) led an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>Crl stimulates sigma activity (S) led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase (figuration 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Crl stimulates sigma activity (S) led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase (figure 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase (figure 3A).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Crl stimulates sigma activity (S) may lead to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Crl stimulates sigma activity (S) will lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Crl stimulates sigma activity (S) will lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Crl stimulates sigma activity (S), in turn, is leading to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>DNA (nCaRE)-ref1 is able to lead to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>DNA (nCaRE)-ref1 may lead to C2+e transcriptional deletion (figure 3A).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>DNA (nCaRE)-ref1 will lead to C2+e transcriptional deletion coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive load in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 is able to lead a substitution of a positive load in a highly conserved transmembrane domain (R496S) (picture 3A).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (figuration 3A).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 was able to lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) when the cells were grown in rich environments.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 will lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14, in turn, is leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D leads to a synergistic activation of 40 to 50 folds of the promoter ANA coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D leads to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to a synergistic activation of 40 to 50 folds of the promoter ANA (figure 3A).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C or MEF2D may lead to a synergistic activation of 40 to 50 folds of the promoter ANA coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D can lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D is able to lead a synergistic activation of 40 to 50 times that of the ANA promoter (picture 3A).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D leads to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D was able to lead to a synergistic activation of 40 to 50 times that of the ANA promoter when the cells were grown in rich environments.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D, in turn, is leading to a synergistic activation of 40 to 50 times that of the ANA promoter regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D has led in a 40 to 50-fold synergistic activation of the aF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the aF promoter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D may lead to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>GATA-4 cotransformation with MEF2A, MEF2C or MEF2D was able to lead to a 40 to 50-fold synergistic activation of the aF promoter when the cells were grown in rich environments.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>GM2 can lead to a neurological disease, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>GM2 genetic deficiency is leading to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>GM2 genetic deficiency led a neurological disorder to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>GM2 genetic deficiency may lead to a neurological disorder (figure 3A).</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>GM2 may lead to a neurological disease coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>GM2 will lead to a neurological disease coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction This leads to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction closer to the transduction pathway of the putative signal that modulates htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction genetic deficiency of the GM2 activator leads to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction mutation of cutting at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction phosphorylation of MuSK NPXY site leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction phosphorylation of the MuSK site NPXY leads to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction this leads to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction a C---A transversion following the helix of the last intron of the ERCC-3 allele-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a C---A transversion following the helix of the last intron of the ERCC-3 allele</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction loss of FOm-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">loss of FOm</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction DNA (nCaRE)-ref1 leads to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction This leads to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a closer examination of the transduction pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a point mutation (GTC---ATC) in codon 383 leads to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a point mutation at the application site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a punctual mutation (GTC----ATC) in codon 383 leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction cut switch at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction sequence selection experience leads to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction the closest test to the transduction pathway of putative signals that modulates the transcription htrA leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction the sequence selection experiment leads to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D-ref1 is able to lead to transcriptional suppression a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction Crl stimulates sigma activity (S)-ref1 is able to lead to transcriptional suppression an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14-ref1 is able to lead to transcriptional suppression a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction GATA-4 co-transfection with MEF2A, MEF2C or MEF2D-ref1 is able to lead to transcriptional suppression a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction This-ref1 is able to lead to transcriptional suppression a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele-ref1 is able to lead to transcriptional suppression an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction a punctual mutation (GTC----ATC) in codon 383-ref1 is able to lead to transcriptional suppression the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction growth of scherichia coli in the presence of nitrate or nitrite-ref1 is able to lead to transcriptional suppression a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction mutation of cut at 5 ends of the intron 5-ref1 is able to lead to transcriptional suppression abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction with two exchanges of frames and a mutation at the fitting site-ref1 is able to lead to transcriptional suppression elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction with two exchanges of frames and a mutation at the fitting site-ref1 is able to lead to transcriptional suppression oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In this homologous part of genes, GBP lacks an exon due to This, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In this homologous part of genes, GBP lacks an exon due to a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In this homologous part of genes, GBP lacks an exon due to a closer analysis of the putative signal transduction pathway that modulates HtrA transcription, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In this homologous part of genes, GBP lacks an exon due to a closer examination of the transduction pathway of putative signals that modulates the transcription htrA, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In this homologous part of genes, GBP lacks an exon due to a point mutation at the pulse site of the third intron, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In this homologous part of genes, GBP lacks an exon due to nCaRE, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In this homologous part of genes, GBP lacks an exon due to the closest test to the transduction pathway of putative signals that modulates the transcription htrA, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In this homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In this homologous part of genes, GBP lacks an exon due to with two exchanges of frames and a mutation at the fitting site, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In this homologous part of genes, GPB does not have an exon due to Crl stimulates sigma activity (S), which inactivates the pulse event of the 5th and may lead to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In this homologous part of genes, GPB does not have an exon due to Crl stimulates sigma activity (S), which inactivates the pulse event of the 5th and may lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In this homologous part of genes, GPB does not have an exon due to This, which inactivates the pulse event of the 5th and may lead to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In this homologous part of genes, GPB does not have an exon due to a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele, which inactivates the pulse event of the 5th and may lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In this homologous part of genes, GPB does not have an exon due to a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele, which inactivates the pulse event of the 5th and may lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In this homologous part of genes, GPB does not have an exon due to a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele, which inactivates the pulse event of the 5th and may lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In this homologous part of genes, GPB does not have an exon due to a closer analysis of the putative signal transduction pathway that modulates HtrA transcription, which inactivates the pulse event of the 5th and may lead to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In this homologous part of genes, GPB does not have an exon due to a closer examination of the transfer pathway of putative signals that modulates the transcription htrA, which inactivates the pulse event of the 5th and may lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In this homologous part of genes, GPB does not have an exon due to a mutation point (GTC---ATC) in codon 383, which inactivates the pulse event of the 5th and may lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In this homologous part of genes, GPB does not have an exon due to phosphorylation of the NPXY MuSK site, which inactivates the pulse event of the 5th and may lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>In this homologous part of the genes, GBP does not have an exon due to Crl stimulates sigma activity (S), which inactivates the pulse segmentation event and leads to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>In this homologous part of the genes, GBP does not have an exon due to GM2, which inactivates the pulse segmentation event and leads to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele, which inactivates the pulse segmentation event and leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a point mutation (GTC---ATC) in codon 383, which inactivates the pulse segmentation event and leads to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>In this homologous part of the genes, GBP does not have an exon due to closer to the transduction pathway of the putative signal that modulates htrA transcription, which inactivates the pulse segmentation event and leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>In this homologous part of the genes, GBP does not have an exon due to closer to the transduction pathway of the putative signal that modulates the htrA transcription, which inactivates the pulse segmentation event and leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>In this homologous part of the genes, GBP does not have an exon due to genetic deficiency of the GM2 activator, which inactivates the pulse segmentation event and leads to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>In this homologous part of the genes, GBP does not have an exon due to growth of scherichia coli in the presence of nitrate or nitrite, which inactivates the pulse segmentation event and leads to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>In this homologous part of the genes, GBP does not have an exon due to nCaRE, which inactivates the pulse segmentation event and leads to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>In this homologous part of the genes, GBP does not have an exon due to phosphorylation of MuSK NPXY site, which inactivates the pulse segmentation event and leads to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>In this homologous part of the genes, GBP does not have an exon due to phosphorylation of the MuSK site NPXY, which inactivates the pulse segmentation event and leads to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>In this homologous part of the genes, GBP does not have an exon due to sequence selection experience, which inactivates the pulse segmentation event and leads to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Loss of TreR function is leading to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Loss of TreR function led to derepression of treB (figuration 3A).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Loss of TreR function led to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Loss of TreR function may lead to derepression of treB (figure 3A).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Loss of TreR function will lead to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>The Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D led to a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>The Crl stimulates sigma (S) activity leads to the an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>The Crl stimulates sigma activity (S) led to the an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>The Crl stimulates sigma activity (S) led to the an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>The Crl stimulates sigma activity (S) will lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>The G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leads to the a substitution of a positive load in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>The G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive load in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>The G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive charge in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>The GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>The GATA-4 co-transfection with MEF2A, MEF2C or MEF2D will lead to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>The GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leads to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>The GATA-4 cotransformation with MEF2A, MEF2C or MEF2D led to the a 40 to 50-fold synergistic activation of the aF promoter appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>The GM2 genetic deficiency can lead to the a neurological disorder appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>The GM2 led to the a neurological disease appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>The Loss of TreR function led to the derepression of treB appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>The This can lead to the a wide diversity of nebulin and nebule isoforms appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>The This leads to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>The This led to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>The This led to the a wide diversity of nebulin and nebule isoforms appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>The This led to the synergistic activation of ANA and other target promoters of MEF2 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>The a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leads to the an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>The a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>The a C--A transversion after the last intron sternalization aceptors of the ERCC-3 can lead to the an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>The a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>The a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription can lead to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>The a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>The a closer examination of the transfer pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>The a closer examination of the transfer pathway of putative signals that modulates the transcription htrA leads to the the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>The a mutation point (GTC---ATC) in codon 383 can lead to the the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>The a punctual mutation (GTC----ATC) in codon 383 leads to the the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>The a punctual mutation (GTC----ATC) in codon 383 led to the the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>The closer to the transduction pathway of the putative signal that modulates htrA transcription can lead to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>The closer to the transduction pathway of the putative signal that modulates htrA transcription led to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>The closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the the identification of two new genes appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>The cut switch at 5 ends of the intron 5 leads to the abnormal exon 5 and exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>The cut switch at 5 ends of the intron 5 led to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>The genetic deficiency of the GM2 activator can lead to the a neurological disorder appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>The genetic deficiency of the GM2 activator led to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>The genetic deficiency of the GM2 activator led to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>The genetic deficiency of the GM2 activator led to the a neurological disorder appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>The growth of scherichia coli in the presence of nitrate or nitrite led to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>The growth of scherichia coli in the presence of nitrate or nitrite led to the a 45% drop in expression appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>The mutation of cut at 5 ends of the intron 5 led to the abnormal exon 5 and portion of exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>The mutation of cutting at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>The mutation of cutting at 5 ends of the intron 5 led to the normal exon 5 and portion of exon 6 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>The mutations identified include: Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the ANA promoter, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>The mutations identified include: Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the ANA promoter, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>The mutations identified include: DNA (nCaRE)-ref1 that led to C2+ and transcriptional deletion, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>The mutations identified include: DNA (nCaRE)-ref1 that led to C2+e transcriptional deletion, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>The mutations identified include: GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the aF promoter, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>The mutations identified include: GM2 genetic deficiency leading to a neurological disorder, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>The mutations identified include: GM2 genetic deficiency that led to a neurological disorder, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>The mutations identified include: GM2 that led to a neurological disease, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>The mutations identified include: Loss of TreR function that led to derepression of treB, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>The mutations identified include: This that led to a wide diversity of nebulin and nebule isoforms, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>The mutations identified include: a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>The mutations identified include: a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>The mutations identified include: a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth intron, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>The mutations identified include: a punctual mutation (GTC----ATC) in codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>The mutations identified include: cut switch at 5 ends of the intron 5 leading to abnormal exon 5 and exon 6, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>The mutations identified include: mutation of cutting at 5 ends of the intron 5 that led to normal exon 5 and portion of exon 6, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>The mutations identified include: phosphorylation of the MuSK site NPXY leading to capture of a protein containing phosphorosine binding domains, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>The mutations identified include: phosphorylation of the MuSK site NPXY that led to capture of a phosphorosine binding protein, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>The mutations identified include: phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphotyrosine, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>The mutations identified include: sequence selection experience that led to BRE identification, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>The mutations identified include: sequence selection experience that led to BRE identification, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>The mutations identified include: the closest test to the transduction pathway of putative signals that modulates the transcription htrA leading to identification of two new genes, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>The mutations identified include: the sequence selection experiment that led to the identification of BRE, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>The mutations identified include: two changes in the picture and one mutation at the fitting site that led to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site leading to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>The mutations identified include: with two exchanges of frames and a mutation at the fitting site that led to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>The nCaRE can lead to the C2+e-mediated transcriptional supression appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>The nCaRE leads to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>The phosphorylation of the MuSK site NPXY leads to the capture of a protein containing phosphorosine binding domains appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>The phosphorylation of the MuSK site NPXY led to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>The phosphorylation of the NPXY MuSK site can lead to the recruitment of a domain protein bound to phosphotyrosine appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>The phosphorylation of the NPXY MuSK site will lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>The phosphorylation of the NPXY site of MuSK leads to the recovery of a domain protein bound to phosphotyrosine appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>The phosphorylation of the NPXY site of MuSK led to the recovery of a domain protein bound to phosphotyrosine appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>The phosphorylation of the site NPXY MuSK can lead to the recovery of a domain protein bound to phosphorosine appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>The phosphorylation of the site NPXY MuSK leads to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>The phosphorylation of the site NPXY MuSK leads to the recovery of a domain protein bound to phosphotyrosine appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>The phosphorylation of the site NPXY MuSK led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>The sequence selection experience led to the BRE identification appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>The the closest test to the putative signal transduction pathway that modulates the htrA transcription can lead to the identification of two new genes appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>The the closest test to the putative signal transduction pathway that modulates the htrA transcription leads to the identification of two new genes appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>The this leads to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>The this leads to the a substantial diversity of isoforms of nebulin and nebulae appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>The this leads to the a substantial diversity of isoforms of nebulin and nebulette appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>The this led to the a substantial diversity of isoforms of nebulin and nebulette appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to loss of OmpF.</text>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to the loss of OmpF.</text>
                    <arg n="0">the loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to two changes in the picture and one mutation at the ear site.</text>
                    <arg n="0">two changes in the picture and one mutation at the ear site</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>The two changes in the picture and one mutation at the fitting site led to the oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>The with two exchanges of frames and a mutation at the fitting site led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>The with two exchanges of frames and a mutation at the fitting site will lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>These data suggest that Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D may lead to a 40 to 50-fold synergistic activation of the ANA promoter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>These data suggest that Crl stimulates sigma activity (S) led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>These data suggest that Crl stimulates sigma activity (S) was able to lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>These data suggest that Crl stimulates sigma activity (S) was able to lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>These data suggest that DNA (nCaRE)-ref1 led to C2+ and transcriptional deletion that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>These data suggest that DNA (nCaRE)-ref1 may lead to C2+e transcriptional deletion that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>These data suggest that GATA-4 co-transfection with MEF2A, MEF2C or MEF2D led to a synergistic activation of 40 to 50 folds of the promoter ANA that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>These data suggest that GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>These data suggest that This led to synergistic activation of ANA and other target promoters of MEF2 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>These data suggest that This may lead to a wide diversity of nebulae and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>These data suggest that This may lead to a wide diversity of nebulin and nebule isoforms that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>These data suggest that This was able to lead to a wide diversity of nebulae and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>These data suggest that a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>These data suggest that a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele was able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>These data suggest that a C--A transversion after the last intron sternalization aceptors of the ERCC-3 led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>These data suggest that a closer analysis of the putative signal transduction pathway that modulates HtrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>These data suggest that a closer examination of the transduction pathway of putative signals that modulates the transcription htrA may lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>These data suggest that a mutation point (GTC---ATC) in codon 383 was able to lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>These data suggest that a point mutation at the application site of the third intron led to ligation of the second to the fourth exon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>These data suggest that a point mutation at the application site of the third intron may lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>These data suggest that a point mutation at the pulse site of the third intron may lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>These data suggest that a punctual mutation (GTC----ATC) in codon 383 led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>These data suggest that a punctual mutation (GTC----ATC) in codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>These data suggest that closer to the transduction pathway of the putative signal that modulates htrA transcription led to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>These data suggest that closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>These data suggest that growth of scherichia coli in the presence of nitrate or nitrite was able to lead to a 45% drop in expression that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>These data suggest that nCaRE led to C2+e-mediated transcriptional supression that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>These data suggest that nCaRE may lead to C2+e-mediated transcriptional supression that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>These data suggest that phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>These data suggest that sequence selection experience led to BRE identification that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>These data suggest that the sequence selection experiment was able to lead to the identification of BRE that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>These data suggest that this led to a substantial diversity of isoforms of nebulin and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>These data suggest that this was able to lead to a substantial diversity of isoforms of nebulin and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>This DNA of patients contains Crl stimulates sigma activity (S) allele that can lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>This DNA of patients contains Crl stimulates sigma activity (S) allele that can lead to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>This DNA of patients contains DNA (nCaRE)-ref1 allele that can lead to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>This DNA of patients contains GM2 allele that can lead to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>This DNA of patients contains a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>This DNA of patients contains a closer examination of the transduction pathway of putative signals that modulates the transcription htrA allele that can lead to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>This DNA of patients contains a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>This DNA of patients contains cut switch at 5 ends of the intron 5 that led to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>This DNA of patients contains genetic deficiency of the GM2 activator allele that can lead to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>This DNA of patients contains growth of scherichia coli in the presence of nitrate or nitrite that led to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>This DNA of patients contains mutation of cutting at 5 ends of the intron 5 that led to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>This DNA of patients contains nCaRE allele that can lead to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY allele that can lead to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY allele that can lead to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>This DNA of patients contains phosphorylation of the MuSK site NPXY that led to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>This DNA of patients contains phosphorylation of the NPXY site of MuSK that led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>This DNA of patients contains phosphorylation of the site NPXY MuSK that led to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>This DNA of patients contains phosphorylation of the site NPXY MuSK that led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>This DNA of patients contains sequence selection experience allele that can lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>This DNA of patients contains this that led to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>This DNA of patients contains with two exchanges of frames and a mutation at the fitting site allele that can lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) leading to an increase in the transcription rate of a subset of rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>This base pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) that has led to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>This base pair G:C is also the strongest determinant in DNA (nCaRE)-ref1 that has led to C2+e transcriptional deletion (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>This base pair G:C is also the strongest determinant in GM2 genetic deficiency leads to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>This base pair G:C is also the strongest determinant in Loss of TreR function leading to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>This base pair G:C is also the strongest determinant in Loss of TreR function that has led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>This base pair G:C is also the strongest determinant in This leading to synergistic activation of ANA and other target promoters of MEF2 (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>This base pair G:C is also the strongest determinant in This leads to synergistic activation of ANA and other target promoters of MEF2 (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>This base pair G:C is also the strongest determinant in This that led to a wide diversity of nebulae and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>This base pair G:C is also the strongest determinant in a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>This base pair G:C is also the strongest determinant in a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele that has led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (Lagrange et al., 1998).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>This base pair G:C is also the strongest determinant in a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (Lagrange et al., 1998).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>This base pair G:C is also the strongest determinant in a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (Lagrange et al., 1998).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>This base pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 leads to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>This base pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>This base pair G:C is also the strongest determinant in a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop (Lagrange et al., 1998).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the application site of the third intron that has led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>This base pair G:C is also the strongest determinant in closer to the transduction pathway of the putative signal that modulates htrA transcription leading to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>This base pair G:C is also the strongest determinant in closer to the transduction pathway of the putative signal that modulates htrA transcription that has led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>This base pair G:C is also the strongest determinant in closer to the transduction pathway of the putative signal that modulates the htrA transcription that led to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>This base pair G:C is also the strongest determinant in cut switch at 5 ends of the intron 5 that has led to abnormal exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>This base pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator that has led to a neurological disease (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>This base pair G:C is also the strongest determinant in nCaRE that has led to C2+e-mediated transcriptional supression (Lagrange et al., 1998).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>This base pair G:C is also the strongest determinant in nCaRE that led to C2+e-mediated transcriptional supression (Lagrange et al., 1998).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of MuSK NPXY site leads to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the NPXY MuSK site leads to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>This base pair G:C is also the strongest determinant in phosphorylation of the site NPXY MuSK that led to recovery of a domain protein bound to phosphorosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>This base pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA that has led to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>This base pair G:C is also the strongest determinant in this leads to a substantial diversity of isoforms of nebulin and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>This base pair G:C is also the strongest determinant in this that has led to a substantial diversity of isoforms of nebulin and nebulette (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>This base pair G:C is also the strongest determinant in this that led to a substantial diversity of isoforms of nebulin and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>This base pair G:C is also the strongest determinant in two changes in the picture and one mutation at the fitting site leading to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction (Lagrange et al., 1998).</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>This basic pair G:C is also the strongest determinant in Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the ANA promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>This basic pair G:C is also the strongest determinant in Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the ANA promoter (Lagrange et al., 1998).</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>This basic pair G:C is also the strongest determinant in Crl stimulates sigma activity (S) that leads to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase (Lagrange et al., 1998).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>This basic pair G:C is also the strongest determinant in DNA (nCaRE)-ref1 leading to C2+e transcriptional deletion (Lagrange et al., 1998).</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>This basic pair G:C is also the strongest determinant in GATA-4 cotransformation with MEF2A, MEF2C or MEF2D leading to a 40 to 50-fold synergistic activation of the aF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>This basic pair G:C is also the strongest determinant in GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that leads to a 40 to 50-fold synergistic activation of the aF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>This basic pair G:C is also the strongest determinant in GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the aF promoter (Lagrange et al., 1998).</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>This basic pair G:C is also the strongest determinant in This leading to a wide diversity of nebulae and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>This basic pair G:C is also the strongest determinant in This that leads to a wide diversity of nebulin and nebule isoforms (Lagrange et al., 1998).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>This basic pair G:C is also the strongest determinant in a C--A transversion after the last intron sternalization aceptors of the ERCC-3 that led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid (Lagrange et al., 1998).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>This basic pair G:C is also the strongest determinant in a closer examination of the transduction pathway of putative signals that modulates the transcription htrA that leads to the identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the application site of the third intron that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the pulse site of the third intron leading to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the pulse site of the third intron that leads to ligation of the second to the fourth intron (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>This basic pair G:C is also the strongest determinant in a punctual mutation (GTC----ATC) in codon 383 that leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter (Lagrange et al., 1998).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>This basic pair G:C is also the strongest determinant in cut switch at 5 ends of the intron 5 that leads to normal exon 5 and portion of exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>This basic pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator leading to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>This basic pair G:C is also the strongest determinant in genetic deficiency of the GM2 activator that leads to a neurological disorder (Lagrange et al., 1998).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>This basic pair G:C is also the strongest determinant in mutation of cutting at 5 ends of the intron 5 that leads to normal exon 5 and portion of exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the MuSK site NPXY that led to recovery of a protein bound to phosphorosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the NPXY MuSK site leading to recruitment of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the NPXY site of MuSK that leads to recovery of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the NPXY site of MuSK that led to recovery of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphorosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>This basic pair G:C is also the strongest determinant in phosphorylation of the site NPXY MuSK that leads to recovery of a domain protein bound to phosphotyrosine (Lagrange et al., 1998).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>This basic pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA leading to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>This basic pair G:C is also the strongest determinant in the closest test to the transduction pathway of putative signals that modulates the transcription htrA that led to identification of two new genes (Lagrange et al., 1998).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>This basic pair G:C is also the strongest determinant in the sequence selection experiment that leads to the identification of BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>This basic pair G:C is also the strongest determinant in this that led to a substantial diversity of isoforms of nebulin and nebulae (Lagrange et al., 1998).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>This basic pair G:C is also the strongest determinant in two changes in the picture and one mutation at the fitting site leading to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction (Lagrange et al., 1998).</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>This basic pair G:C is also the strongest determinant in with two exchanges of frames and a mutation at the fitting site leading to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction (Lagrange et al., 1998).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>This can lead to a wide diversity of nebulae and nebulae (figuration 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>This can lead to a wide diversity of nebulins and nebule isoforms, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>This can lead to synergistic activation of ANA and other target promoters of MEF2, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>This can lead to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>This data suggests that Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D has led to a 40 to 50-fold synergistic activation of the ANA promoter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>This data suggests that Crl stimulates sigma (S) activity led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>This data suggests that Crl stimulates sigma activity (S) can lead to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>This data suggests that Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>This data suggests that Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>This data suggests that Crl stimulates sigma activity (S) led to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>This data suggests that DNA (nCaRE)-ref1 was able to lead to C2+ and transcriptional deletion that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>This data suggests that GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>This data suggests that GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D led to a synergistic activation of 40 to 50 times that of the ANA promoter working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>This data suggests that GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D was able to lead to a synergistic activation of 40 to 50 times that of the ANA promoter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>This data suggests that GATA-4 cotransformation with MEF2A, MEF2C or MEF2D was able to lead to a 40 to 50-fold synergistic activation of the aF promoter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>This data suggests that GM2 genetic deficiency can lead to a neurological disorder that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>This data suggests that GM2 led to a neurological disease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>This data suggests that This led to a wide diversity of nebulae and nebulae that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>This data suggests that This led to a wide diversity of nebulins and nebule isoforms working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>This data suggests that This led to synergistic activation of ANA and other target promoters of MEF2 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>This data suggests that This led to synergistic activation of ANA and other target promoters of MEF2 working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>This data suggests that This was able to lead to a wide diversity of nebulae and nebulae that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>This data suggests that This will lead to a wide diversity of nebulin and nebule isoforms that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>This data suggests that a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>This data suggests that a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele was able to lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>This data suggests that a C--A transversion after the last intron sternalization aceptors of the ERCC-3 can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>This data suggests that a closer analysis of the putative signal transduction pathway that modulates HtrA transcription can lead to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>This data suggests that a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>This data suggests that a closer examination of the transduction pathway of putative signals that modulates the transcription htrA will lead to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>This data suggests that a closer examination of the transfer pathway of putative signals that modulates the transcription htrA will lead to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>This data suggests that a mutation point (GTC---ATC) in codon 383 led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>This data suggests that a mutation point (GTC---ATC) in codon 383 was able to lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>This data suggests that a point mutation (GTC---ATC) in codon 383 led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>This data suggests that a point mutation (GTC---ATC) in codon 383 will lead to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>This data suggests that a point mutation at the pulse site of the third intron was able to lead to ligation of the second to the fourth intron that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 was able to lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>This data suggests that a punctual mutation (GTC----ATC) in codon 383 will lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates htrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates the htrA transcription was able to lead to the identification of two new genes that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>This data suggests that closer to the transduction pathway of the putative signal that modulates the htrA transcription will lead to the identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>This data suggests that genetic deficiency of the GM2 activator will lead to a neurological disorder that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>This data suggests that mutation of cut at 5 ends of the intron 5 led to abnormal exon 5 and portion of exon 6 working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>This data suggests that mutation of cutting at 5 ends of the intron 5 has led to normal exon 5 and portion of exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>This data suggests that nCaRE led to C2+e-mediated transcriptional supression working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY can lead to capture of a phosphorosine binding protein that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY can lead to capture of a protein containing phosphorosine binding domains that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY has led to capture of a phosphorosine binding protein that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY has led to recovery of a protein bound to phosphorosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY was able to lead to capture of a phosphorosine binding protein that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY was able to lead to capture of a protein containing phosphorosine binding domains that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>This data suggests that phosphorylation of the MuSK site NPXY was able to lead to recovery of a protein bound to phosphorosine that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>This data suggests that phosphorylation of the NPXY MuSK site has led to recruitment of a domain protein bound to phosphotyrosine that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>This data suggests that phosphorylation of the site NPXY MuSK led to recovery of a domain protein bound to phosphorosine working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>This data suggests that sequence selection experience was able to lead to BRE identification that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>This data suggests that sequence selection experience will lead to BRE identification that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>This data suggests that the closest test to the putative signal transduction pathway that modulates the htrA transcription can lead to identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>This data suggests that the closest test to the putative signal transduction pathway that modulates the htrA transcription led to identification of two new genes working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>This data suggests that the closest test to the transduction pathway of putative signals that modulates the transcription htrA will lead to identification of two new genes that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>This data suggests that the sequence selection experiment will lead to the identification of BRE that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>This data suggests that this was able to lead to a substantial diversity of isoforms of nebulin and nebulette that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site can lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site has led to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>This data suggests that with two exchanges of frames and a mutation at the fitting site will lead to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>This has led in a wide diversity of nebulae and nebulae, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>This has led in a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>This has led in synergistic activation of ANA and other target promoters of MEF2, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>This is able to lead a wide diversity of nebulins and nebule isoforms (picture 3A).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>This is able to lead to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>This is able to lead to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>This is able to lead to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>This leading to a wide diversity of nebulins and nebule isoforms, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>This leading to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>This leading to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>This leads to a wide diversity of nebulin and nebule isoforms coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>This led to a wide diversity of nebulins and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>This patient DNA contains Crl stimulates sigma activity (S) leads to an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>This patient DNA contains Crl stimulates sigma activity (S) which leads to an increase in the transcription rate of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>This patient DNA contains G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>This patient DNA contains G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>This patient DNA contains GATA-4 co-transfection with MEF2A, MEF2C or MEF2D leads to a synergistic activation of 40 to 50 folds of the promoter ANA.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>This patient DNA contains GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D that can lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>This patient DNA contains GM2 that can lead to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>This patient DNA contains GM2 which leads to a neurological disease.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>This patient DNA contains This that can lead to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>This patient DNA contains a C--A transversion after the last intron sternalization aceptors of the ERCC-3 that can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>This patient DNA contains a point mutation at the application site of the third intron that can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>This patient DNA contains a point mutation at the application site of the third intron which leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>This patient DNA contains a punctual mutation (GTC----ATC) in codon 383 leads to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>This patient DNA contains a punctual mutation (GTC----ATC) in codon 383 that can lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>This patient DNA contains a punctual mutation (GTC----ATC) in codon 383 that can lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>This patient DNA contains closer to the transduction pathway of the putative signal that modulates htrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>This patient DNA contains closer to the transduction pathway of the putative signal that modulates htrA transcription which leads to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>This patient DNA contains cut switch at 5 ends of the intron 5 which leads to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>This patient DNA contains growth of scherichia coli in the presence of nitrate or nitrite leads to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>This patient DNA contains mutation of cutting at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>This patient DNA contains nCaRE that can lead to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>This patient DNA contains nCaRE which leads to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>This patient DNA contains phosphorylation of the MuSK site NPXY that can lead to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>This patient DNA contains phosphorylation of the MuSK site NPXY which leads to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>This patient DNA contains phosphorylation of the NPXY MuSK site that can lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>This patient DNA contains phosphorylation of the NPXY site of MuSK which leads to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>This patient DNA contains sequence selection experience that can lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>This patient DNA contains the closest test to the putative signal transduction pathway that modulates the htrA transcription that can lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>This patient DNA contains the closest test to the transduction pathway of putative signals that modulates the transcription htrA which leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>This patient DNA contains this which leads to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>This patients DNA contains loss of OmpF leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>This patients DNA contains nCaRE leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>This was caused by Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D which leading to a 40 to 50-fold synergistic activation of the ANA promoter.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>This was caused by Crl stimulates sigma (S) activity leading to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>This was caused by Crl stimulates sigma (S) activity that may lead to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>This was caused by Crl stimulates sigma (S) activity which has led to an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma (S) activity</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS regulon genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>This was caused by Crl stimulates sigma activity (S) leading to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>This was caused by Crl stimulates sigma activity (S) that leads to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>This was caused by Crl stimulates sigma activity (S) that led to an increase in the rate of transcription of a subset of rpoS genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>This was caused by Crl stimulates sigma activity (S) which leading to an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase.</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>This was caused by DNA (nCaRE)-ref1 leading to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>This was caused by DNA (nCaRE)-ref1 leads to C2+e transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+e transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>This was caused by DNA (nCaRE)-ref1 that leads to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>This was caused by DNA (nCaRE)-ref1 which leading to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>This was caused by DNA (nCaRE)-ref1 which led to C2+ and transcriptional deletion.</text>
                    <arg n="0">DNA (nCaRE)-ref1</arg>
                    <arg n="1">C2+ and transcriptional deletion</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>This was caused by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>This was caused by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14 which has led to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>This was caused by G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus cutting site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D that may lead to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>This was caused by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D which has led to a synergistic activation of 40 to 50 times that of the ANA promoter.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>This was caused by GATA-4 cotransformation with MEF2A, MEF2C or MEF2D that led to a 40 to 50-fold synergistic activation of the aF promoter.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>This was caused by GM2 genetic deficiency leading to a neurological disorder.</text>
                    <arg n="0">GM2 genetic deficiency</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>This was caused by Loss of TreR function that can lead to derepression of treB.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>This was caused by This leading to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>This was caused by This that can lead to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>This was caused by This that led to a wide diversity of nebulin and nebule isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>This was caused by This that may lead to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>This was caused by This which leading to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>This was caused by This which leading to synergistic activation of ANA and other target promoters of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>This was caused by a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele that can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>This was caused by a C--A transversion after the last intron sternalization aceptors of the ERCC-3 that can lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>This was caused by a closer analysis of the putative signal transduction pathway that modulates HtrA transcription that can lead to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>This was caused by a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>This was caused by a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription which leading to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>This was caused by a closer examination of the transduction pathway of putative signals that modulates the transcription htrA which leading to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>This was caused by a closer examination of the transduction pathway of putative signals that modulates the transcription htrA which led to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>This was caused by a closer examination of the transfer pathway of putative signals that modulates the transcription htrA leading to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>This was caused by a closer examination of the transfer pathway of putative signals that modulates the transcription htrA leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>This was caused by a mutation point (GTC---ATC) in codon 383 that can lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>This was caused by a mutation point (GTC---ATC) in codon 383 that leads to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>This was caused by a mutation point (GTC---ATC) in codon 383 that led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>This was caused by a point mutation (GTC---ATC) in codon 383 which leading to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>This was caused by a point mutation at the application site of the third intron which has led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>This was caused by a point mutation at the pulse site of the third intron leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>This was caused by a point mutation at the pulse site of the third intron leading to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>This was caused by a point mutation at the pulse site of the third intron that leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>This was caused by a point mutation at the pulse site of the third intron that led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>This was caused by a point mutation at the pulse site of the third intron that may lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 leads to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 that may lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>This was caused by a punctual mutation (GTC----ATC) in codon 383 which led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>This was caused by closer to the transduction pathway of the putative signal that modulates htrA transcription which led to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>This was caused by closer to the transduction pathway of the putative signal that modulates the htrA transcription which leading to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>This was caused by cut switch at 5 ends of the intron 5 that leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>This was caused by cut switch at 5 ends of the intron 5 that may lead to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>This was caused by cut switch at 5 ends of the intron 5 that may lead to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>This was caused by cut switch at 5 ends of the intron 5 which has led to abnormal exon 5 and exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>This was caused by genetic deficiency of the GM2 activator leading to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>This was caused by genetic deficiency of the GM2 activator that can lead to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>This was caused by genetic deficiency of the GM2 activator that can lead to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>This was caused by genetic deficiency of the GM2 activator that leads to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>This was caused by growth of scherichia coli in the presence of nitrate or nitrite which leading to a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>This was caused by mutation of cut at 5 ends of the intron 5 that leads to abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>This was caused by mutation of cut at 5 ends of the intron 5 which led to abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>This was caused by mutation of cutting at 5 ends of the intron 5 that leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>This was caused by mutation of cutting at 5 ends of the intron 5 that led to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>This was caused by nCaRE that can lead to C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>This was caused by phosphorylation of the MuSK site NPXY that leads to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>This was caused by phosphorylation of the MuSK site NPXY that led to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>This was caused by phosphorylation of the MuSK site NPXY which leading to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>This was caused by phosphorylation of the MuSK site NPXY which leading to recovery of a protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>This was caused by phosphorylation of the NPXY site of MuSK which led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>This was caused by phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>This was caused by phosphorylation of the site NPXY MuSK that may lead to recovery of a domain protein bound to phosphorosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>This was caused by phosphorylation of the site NPXY MuSK which has led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>This was caused by sequence selection experience that may lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>This was caused by the closest test to the putative signal transduction pathway that modulates the htrA transcription leads to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>This was caused by the closest test to the putative signal transduction pathway that modulates the htrA transcription that can lead to identification of two new genes.</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>This was caused by the closest test to the transduction pathway of putative signals that modulates the transcription htrA leading to identification of two new genes.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>This was caused by the sequence selection experiment which has led to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>This was caused by this that may lead to a substantial diversity of isoforms of nebulin and nebulae.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>This was caused by this that may lead to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>This was caused by this which has led to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>This was caused by two changes in the picture and one mutation at the fitting site that can lead to oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>This will lead to a wide diversity of nebulae and nebulae.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulae and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>This will lead to a wide diversity of nebulins and nebule isoforms coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulins and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to the loss of OmpF.</text>
                    <arg n="0">the loss of OmpF</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to nCaRE.</text>
                    <arg n="0">nCaRE</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>a 40 to 50-fold synergistic activation of the ANA promoter is led to Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>a 40 to 50-fold synergistic activation of the ANA promoter was led to Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">Co-transfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>a 40 to 50-fold synergistic activation of the aF promoter is led to GATA-4 cotransformation with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">GATA-4 cotransformation with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a 40 to 50-fold synergistic activation of the aF promoter</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele can lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figuration 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele is able to lead to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figure 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele leads to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figuration 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele led to an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein (figure 3A).</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele led to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele may lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C (figure 3A).</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele was able to lead to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C when the cells were grown in rich environments.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele, in turn, is leading to an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactive frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele is able to lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C (figure 3A).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele will lead to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele, in turn, is leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a C---A transversion in the last intron acceptor sequence of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leading to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 leads to an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>a C--A transversion after the last intron sternalization aceptors of the ERCC-3 led an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a C--A transversion after the last intron sternalization aceptors of the ERCC-3</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins C-termoid</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription led to the identification of two new genes (figure 3A).</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>a closer analysis of the putative signal transduction pathway that modulates HtrA transcription may lead to the identification of two new genes.</text>
                    <arg n="0">a closer analysis of the putative signal transduction pathway that modulates HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription has led in the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription leads to the identification of two new genes.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA is able to lead to the identification of two new genes (figure 3A).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>a closer examination of the transduction pathway of putative signals that modulates the transcription htrA led to the identification of two new genes (figuration 3A).</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA will lead to the identification of two new genes coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>a closer examination of the transfer pathway of putative signals that modulates the transcription htrA, in turn, is leading to the identification of two new genes regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>a mutation point (GTC---ATC) in codon 383 has led in the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>a mutation point (GTC---ATC) in codon 383 is able to lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>a mutation point (GTC---ATC) in codon 383 leading to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>a mutation point (GTC---ATC) in codon 383 leading to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>a mutation point (GTC---ATC) in codon 383 leading to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>a mutation point (GTC---ATC) in codon 383 led to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>a mutation point (GTC---ATC) in codon 383 led to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop (figure 3A).</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>a mutation point (GTC---ATC) in codon 383 may lead to the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>a mutation point (GTC---ATC) in codon 383, in turn, is leading to the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>a neurological disease is led by GM2.</text>
                    <arg n="0">GM2</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>a point mutation (GTC---ATC) in codon 383 can lead to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>a point mutation (GTC---ATC) in codon 383 has led in conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>a point mutation (GTC---ATC) in codon 383 is able to lead to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>a point mutation (GTC---ATC) in codon 383 leads to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>a point mutation (GTC---ATC) in codon 383 led conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>a point mutation (GTC---ATC) in codon 383 led to conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop (figure 3A).</text>
                    <arg n="0">a point mutation (GTC---ATC) in codon 383</arg>
                    <arg n="1">conservative substitution of isoleucine for valine in the transporters fifth extracellular putative loop</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>a point mutation at the application site of the third intron has led in ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>a point mutation at the application site of the third intron is able to lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>a point mutation at the application site of the third intron leads to ligation of the second to the fourth exon coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>a point mutation at the pulse site of the third intron is able to lead to ligation of the second to the fourth intron (figure 3A).</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>a point mutation at the pulse site of the third intron is leading to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>a point mutation at the pulse site of the third intron leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>a point mutation at the pulse site of the third intron may lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>a punctual mutation (GTC----ATC) in codon 383 has led in conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>a punctual mutation (GTC----ATC) in codon 383 is able to lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>a punctual mutation (GTC----ATC) in codon 383 leading to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>a punctual mutation (GTC----ATC) in codon 383 leading to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>a punctual mutation (GTC----ATC) in codon 383 led to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>a punctual mutation (GTC----ATC) in codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>a punctual mutation (GTC----ATC) in codon 383 led to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>a punctual mutation (GTC----ATC) in codon 383 may lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>a punctual mutation (GTC----ATC) in codon 383 was able to lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter when the cells were grown in rich environments.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>a punctual mutation (GTC----ATC) in codon 383 was able to lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter when the cells were grown in rich environments.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>a punctual mutation (GTC----ATC) in codon 383 will lead to conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>a punctual mutation (GTC----ATC) in codon 383 will lead to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>a substantial diversity of isoforms of nebulin and nebulette was led by this.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>a substitution of a positive load in a highly conserved transmembrane domain (R496S) was led by G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of the slice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>a synergistic activation of 40 to 50 folds of the promoter ANA is led by GATA-4 co-transfection with MEF2A, MEF2C or MEF2D.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 folds of the promoter ANA</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>a synergistic activation of 40 to 50 times that of the ANA promoter is led by GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D.</text>
                    <arg n="0">GATA-4 co-transfection with MEF2A, MEF2C, or MEF2D</arg>
                    <arg n="1">a synergistic activation of 40 to 50 times that of the ANA promoter</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>a wide diversity of nebulin and nebule isoforms is led to This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a wide diversity of nebulin and nebule isoforms</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>abnormal exon 5 and portion of exon 6 is led by mutation of cut at 5 ends of the intron 5.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>abnormal exon 5 and portion of exon 6 was led by mutation of cut at 5 ends of the intron 5.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>an increase in the rate of transcription of a subset of rpoS genes in the stationary phase was led to Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the rate of transcription of a subset of rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase was led to Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of regulatory rpoS genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase was led to Crl stimulates sigma activity (S).</text>
                    <arg n="0">Crl stimulates sigma activity (S)</arg>
                    <arg n="1">an increase in the transcription rate of a subset of rpoS regulatory genes in the stationary phase</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein was led to a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele.</text>
                    <arg n="0">a C----A transversion following the last intron sneezing aceptor of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into RNAm and an inactivating frameshift into the C-thermoid of the protein</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C was led by a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele.</text>
                    <arg n="0">a C---A transversion in the helix sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">an insertion of 4 bp into the mRNA and an inactivating frame shift in the proteins terminal C</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>capture of a phosphorosine binding protein was led to phosphorylation of the MuSK site NPXY.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>closer to the transduction pathway of the putative signal that modulates htrA transcription can lead to the identification of two new genes (figuration 3A).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>closer to the transduction pathway of the putative signal that modulates htrA transcription led to the identification of two new genes (figuration 3A).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>closer to the transduction pathway of the putative signal that modulates htrA transcription, in turn, is leading to the identification of two new genes regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription is able to lead the identification of two new genes (picture 3A).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription is leading to the identification of two new genes.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription leading to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription led to the identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>closer to the transduction pathway of the putative signal that modulates the htrA transcription may lead to the identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter is led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter was led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">conserved replacement of isoleucine by valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>cut switch at 5 ends of the intron 5 is able to lead to normal exon 5 and portion of exon 6 (figure 3A).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>cut switch at 5 ends of the intron 5 leads to abnormal exon 5 and exon 6 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>cut switch at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>cut switch at 5 ends of the intron 5 leads to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>cut switch at 5 ends of the intron 5 led to abnormal exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and exon 6</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>cut switch at 5 ends of the intron 5 led to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>cut switch at 5 ends of the intron 5 will lead to normal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>derepression of treB is led by Loss of TreR function.</text>
                    <arg n="0">Loss of TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction is led to with two exchanges of frames and a mutation at the fitting site.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>genetic deficiency of the GM2 activator can lead to a neurological disorder, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>genetic deficiency of the GM2 activator can lead to a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>genetic deficiency of the GM2 activator has led in a neurological disease, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>genetic deficiency of the GM2 activator has led in a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>genetic deficiency of the GM2 activator has led in a neurological disorder.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>genetic deficiency of the GM2 activator is able to lead a neurological disorder (picture 3A).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>genetic deficiency of the GM2 activator is able to lead to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>genetic deficiency of the GM2 activator leads to a neurological disease.</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>genetic deficiency of the GM2 activator led to a neurological disease, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disease</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>genetic deficiency of the GM2 activator led to a neurological disorder (figuration 3A).</text>
                    <arg n="0">genetic deficiency of the GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite has led in a 45% drop in expression.</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite is able to lead to a 45% drop in expression (figure 3A).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>growth of scherichia coli in the presence of nitrate or nitrite led to a 45% drop in expression (figure 3A).</text>
                    <arg n="0">growth of scherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% drop in expression</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>identification of two new genes was led to the closest test to the transduction pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>ligation of the second to the fourth exon is led by a point mutation at the pulse site of the third intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>ligation of the second to the fourth intron is led to a point mutation at the pulse site of the third intron.</text>
                    <arg n="0">a point mutation at the pulse site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>mutation of cut at 5 ends of the intron 5 can lead to abnormal exon 5 and portion of exon 6 (figuration 3A).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>mutation of cut at 5 ends of the intron 5 can lead to abnormal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>mutation of cut at 5 ends of the intron 5 may lead to abnormal exon 5 and portion of exon 6 (figure 3A).</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>mutation of cut at 5 ends of the intron 5 may lead to abnormal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>mutation of cut at 5 ends of the intron 5 was able to lead to abnormal exon 5 and portion of exon 6 when the cells were grown in rich environments.</text>
                    <arg n="0">mutation of cut at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>mutation of cutting at 5 ends of the intron 5 can lead to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>mutation of cutting at 5 ends of the intron 5 is leading to normal exon 5 and portion of exon 6.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>mutation of cutting at 5 ends of the intron 5 leading to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>mutation of cutting at 5 ends of the intron 5 led to normal exon 5 and portion of exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>mutation of cutting at 5 ends of the intron 5 may lead to normal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>mutation of cutting at 5 ends of the intron 5 will lead to normal exon 5 and portion of exon 6 coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">mutation of cutting at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>nCaRE can lead to C2+e-mediated transcriptional supression, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>nCaRE has led in C2+e-mediated transcriptional supression.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>nCaRE led C2+e-mediated transcriptional supression to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>nCaRE may lead to C2+e-mediated transcriptional supression (figure 3A).</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>nCaRE, in turn, is leading to C2+e-mediated transcriptional supression regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">nCaRE</arg>
                    <arg n="1">C2+e-mediated transcriptional supression</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>normal exon 5 and portion of exon 6 was led to cut switch at 5 ends of the intron 5.</text>
                    <arg n="0">cut switch at 5 ends of the intron 5</arg>
                    <arg n="1">normal exon 5 and portion of exon 6</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction is led to two changes in the picture and one mutation at the fitting site.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction is led by with two exchanges of frames and a mutation at the fitting site.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>phosphorylation of MuSK NPXY site can lead to recruitment of a domain protein bound to phosphotyrosine (figuration 3A).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>phosphorylation of MuSK NPXY site has led in recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>phosphorylation of MuSK NPXY site leading to recruitment of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>phosphorylation of MuSK NPXY site led recruitment of a domain protein bound to phosphotyrosine to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>phosphorylation of MuSK NPXY site led to recruitment of a domain protein bound to phosphotyrosine (figuration 3A).</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>phosphorylation of MuSK NPXY site led to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>phosphorylation of MuSK NPXY site will lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of MuSK NPXY site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>phosphorylation of the MuSK site NPXY can lead to capture of a protein containing phosphorosine binding domains, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>phosphorylation of the MuSK site NPXY is able to lead capture of a phosphorosine binding protein (picture 3A).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>phosphorylation of the MuSK site NPXY is able to lead to recovery of a protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>phosphorylation of the MuSK site NPXY is leading to capture of a protein containing phosphorosine binding domains.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>phosphorylation of the MuSK site NPXY leading to recovery of a protein bound to phosphorosine, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>phosphorylation of the MuSK site NPXY led to capture of a protein containing phosphorosine binding domains, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a protein containing phosphorosine binding domains</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>phosphorylation of the MuSK site NPXY may lead to recovery of a protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>phosphorylation of the MuSK site NPXY may lead to recovery of a protein bound to phosphorosine coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>phosphorylation of the MuSK site NPXY will lead to capture of a phosphorosine binding protein coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">capture of a phosphorosine binding protein</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>phosphorylation of the NPXY MuSK site is able to lead to recruitment of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>phosphorylation of the NPXY MuSK site leading to recruitment of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>phosphorylation of the NPXY MuSK site may lead to recruitment of a domain protein bound to phosphotyrosine coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>phosphorylation of the NPXY MuSK site, in turn, is leading to recruitment of a domain protein bound to phosphotyrosine regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>phosphorylation of the NPXY site of MuSK can lead to recovery of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>phosphorylation of the NPXY site of MuSK led to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>phosphorylation of the NPXY site of MuSK will lead to recovery of a domain protein bound to phosphotyrosine coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>phosphorylation of the NPXY site of MuSK will lead to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>phosphorylation of the site NPXY MuSK is able to lead to recovery of a domain protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>phosphorylation of the site NPXY MuSK is able to lead to recovery of a domain protein bound to phosphotyrosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>phosphorylation of the site NPXY MuSK leading to recovery of a domain protein bound to phosphotyrosine.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>phosphorylation of the site NPXY MuSK led to recovery of a domain protein bound to phosphotyrosine, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>phosphorylation of the site NPXY MuSK may lead to recovery of a domain protein bound to phosphorosine (figure 3A).</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>phosphorylation of the site NPXY MuSK was able to lead to recovery of a domain protein bound to phosphorosine when the cells were grown in rich environments.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>phosphorylation of the site NPXY MuSK, in turn, is leading to recovery of a domain protein bound to phosphorosine regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">phosphorylation of the site NPXY MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>recovery of a domain protein bound to phosphotyrosine is led by phosphorylation of the NPXY site of MuSK.</text>
                    <arg n="0">phosphorylation of the NPXY site of MuSK</arg>
                    <arg n="1">recovery of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>recovery of a protein bound to phosphorosine was led by phosphorylation of the MuSK site NPXY.</text>
                    <arg n="0">phosphorylation of the MuSK site NPXY</arg>
                    <arg n="1">recovery of a protein bound to phosphorosine</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>recruitment of a domain protein bound to phosphotyrosine was led to phosphorylation of the NPXY MuSK site.</text>
                    <arg n="0">phosphorylation of the NPXY MuSK site</arg>
                    <arg n="1">recruitment of a domain protein bound to phosphotyrosine</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>sequence selection experience can lead to BRE identification, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>sequence selection experience is able to lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>sequence selection experience leads to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>sequence selection experience led to BRE identification, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>sequence selection experience may lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>sequence selection experience was able to lead to BRE identification when the cells were grown in rich environments.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>sequence selection experience will lead to BRE identification.</text>
                    <arg n="0">sequence selection experience</arg>
                    <arg n="1">BRE identification</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>synergistic activation of ANA and other target promoters of MEF2 was led by This.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of ANA and other target promoters of MEF2</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription has led in identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>the closest test to the putative signal transduction pathway that modulates the htrA transcription led to identification of two new genes, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the closest test to the putative signal transduction pathway that modulates the htrA transcription</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA leads to identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA led to identification of two new genes (figuration 3A).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA may lead to identification of two new genes (figure 3A).</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>the closest test to the transduction pathway of putative signals that modulates the transcription htrA may lead to identification of two new genes coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">the closest test to the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop is led by a mutation point (GTC---ATC) in codon 383.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop is led to a mutation point (GTC---ATC) in codon 383.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop was led by a mutation point (GTC---ATC) in codon 383.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter is led by a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter was led by a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter was led to a punctual mutation (GTC----ATC) in codon 383.</text>
                    <arg n="0">a punctual mutation (GTC----ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop is led to a mutation point (GTC---ATC) in codon 383.</text>
                    <arg n="0">a mutation point (GTC---ATC) in codon 383</arg>
                    <arg n="1">the conservative substitution of isoleukin by valine in the putative fifth extracellular transporter loop</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>the identification of BRE was led to the sequence selection experiment.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>the identification of two new genes is led by a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>the identification of two new genes is led by a closer examination of the transduction pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>the identification of two new genes is led to a closer examination of the transfer pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>the identification of two new genes was led by a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>the identification of two new genes was led by a closer examination of the transfer pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">a closer examination of the transfer pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>the identification of two new genes was led by closer to the transduction pathway of the putative signal that modulates the htrA transcription.</text>
                    <arg n="0">closer to the transduction pathway of the putative signal that modulates the htrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>the identification of two new genes was led to a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the HtrA transcription</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>the identification of two new genes was led to a closer examination of the transduction pathway of putative signals that modulates the transcription htrA.</text>
                    <arg n="0">a closer examination of the transduction pathway of putative signals that modulates the transcription htrA</arg>
                    <arg n="1">the identification of two new genes</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>the sequence selection experiment can lead to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>the sequence selection experiment leads to the identification of BRE.</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of BRE</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>this can lead to a substantial diversity of isoforms of nebulin and nebulette (figuration 3A).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>this leading to a substantial diversity of isoforms of nebulin and nebulae, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>this led a substantial diversity of isoforms of nebulin and nebulae to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>this led a substantial diversity of isoforms of nebulin and nebulette to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>this led to a substantial diversity of isoforms of nebulin and nebulae, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>this led to a substantial diversity of isoforms of nebulin and nebulae, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>this may lead to a substantial diversity of isoforms of nebulin and nebulae coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>this may lead to a substantial diversity of isoforms of nebulin and nebulette (figure 3A).</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>this may lead to a substantial diversity of isoforms of nebulin and nebulette.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>this, in turn, is leading to a substantial diversity of isoforms of nebulin and nebulae regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulae</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>this, in turn, is leading to a substantial diversity of isoforms of nebulin and nebulette regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">this</arg>
                    <arg n="1">a substantial diversity of isoforms of nebulin and nebulette</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>two changes in the picture and one mutation at the fitting site has led in oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction.</text>
                    <arg n="0">two changes in the picture and one mutation at the fitting site</arg>
                    <arg n="1">oA1 proteins, removal of a threonine codon at position 290, and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>with two exchanges of frames and a mutation at the fitting site can lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>with two exchanges of frames and a mutation at the fitting site is able to lead elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction (picture 3A).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>with two exchanges of frames and a mutation at the fitting site is able to lead oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction (picture 3A).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>with two exchanges of frames and a mutation at the fitting site leading to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>with two exchanges of frames and a mutation at the fitting site leads to oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction.</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">oA1 vegetated proteins; removal of a threonine codon at position 290; and four mutations of the opposite direction</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>with two exchanges of frames and a mutation at the fitting site may lead to elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction (figure 3A).</text>
                    <arg n="0">with two exchanges of frames and a mutation at the fitting site</arg>
                    <arg n="1">elongated OA1 proteins; removal of a threonine codon at position 290; and four mutations of the reverse direction</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>7 absent mutations, 2 mutations base pair G:C is also the strongest determinant in This leading to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>7 absent mutations, 2 mutations basic pair G:C is also the strongest determinant in This leading to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>7 absent mutations, 2 mutations can lead to shifting in frames (figuration 3A).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>7 absent mutations, 2 mutations data suggests that This led to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>7 absent mutations, 2 mutations data suggests that This led to shifting in frames working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>7 absent mutations, 2 mutations data suggests that This was able to lead to shifting in frames that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>7 absent mutations, 2 mutations has led in shifting in frames, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>7 absent mutations, 2 mutations led shifting in frames to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>7 absent mutations, 2 mutations led to shifting in frames (figure 3A).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>7 absent mutations, 2 mutations was caused by This that can lead to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>7 absent mutations, 2 mutations was caused by This that led to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>7 mutations without sense, 2 mutations base pair G:C is also the strongest determinant in This leading to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>7 mutations without sense, 2 mutations base pair G:C is also the strongest determinant in This that led to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>7 mutations without sense, 2 mutations basic pair G:C is also the strongest determinant in This that leads to table transfer (Lagrange et al., 1998).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>7 mutations without sense, 2 mutations data suggests that This can lead to table transfer that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>7 mutations without sense, 2 mutations is leading to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>7 mutations without sense, 2 mutations leading to table transfer, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>7 mutations without sense, 2 mutations leading to table transfer, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>7 mutations without sense, 2 mutations leading to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>7 mutations without sense, 2 mutations led to table transfer (figuration 3A).</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>7 mutations without sense, 2 mutations was able to lead to table transfer when the cells were grown in rich environments.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>7 mutations without sense, 2 mutations was caused by This that may lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>7 senseless mutations, 2 mutations base pair G:C is also the strongest determinant in This leads to frame shift (Lagrange et al., 1998).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>7 senseless mutations, 2 mutations base pair G:C is also the strongest determinant in This that has led to frame shift (Lagrange et al., 1998).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>7 senseless mutations, 2 mutations basic pair G:C is also the strongest determinant in This leading to frame shift (Lagrange et al., 1998).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>7 senseless mutations, 2 mutations can lead to frame shift (figuration 3A).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>7 senseless mutations, 2 mutations can lead to frame shift, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>7 senseless mutations, 2 mutations led to frame shift, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>7 senseless mutations, 2 mutations led to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>7 senseless mutations, 2 mutations may lead to frame shift coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>Display of the SNU246 gene in yeast base pair G:C is also the strongest determinant in This leading to a defect of in vivo splicing, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>Display of the SNU246 gene in yeast data suggests that This will lead to a defect of in vivo splicing, indicating that the protein is essential for splicing that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>Display of the SNU246 gene in yeast is able to lead a defect of in vivo splicing, indicating that the protein is essential for splicing (picture 3A).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>Display of the SNU246 gene in yeast is leading to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>Display of the SNU246 gene in yeast leads to a defect of in vivo splicing, indicating that the protein is essential for splicing coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>Display of the SNU246 gene in yeast led to a defect of in vivo splicing, indicating that the protein is essential for splicing (figuration 3A).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Display of the SNU246 gene in yeast led to a defect of in vivo splicing, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Display of the SNU246 gene in yeast may lead to a defect of in vivo splicing, indicating that the protein is essential for splicing coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Display of the SNU246 gene in yeast was caused by This which has led to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Display of the SNU246 gene in yeast, in turn, is leading to a defect of in vivo splicing, indicating that the protein is essential for splicing regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This was able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 was caused by This leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 was caused by This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 DNA of patients contains This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This that has led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This that leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This led to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that can lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 will lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 will lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 data suggests that This led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 has led in a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 will lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14, in turn, is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 DNA of patients contains This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 is leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S), an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This that may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This which has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 basic pair G:C is also the strongest determinant in This leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 data suggests that This led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive charge in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 is able to lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 was caused by This which led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 base pair G:C is also the strongest determinant in This leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 has led in a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 is able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (figure 3A).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S), an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 patient DNA contains This leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 patient DNA contains This which leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was caused by This leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 will lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>In 7 mutations without sense, 2 mutations homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>In G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>In G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>In G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>In G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a complex coupling site mutation-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a complex mutation of the coupling site leads to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction a point mutation at the application site of the third intron-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction loss of the TreR function-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">loss of the TreR function</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction the mutation of the splice at 5 ends of the intron 5 leads to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction the mutation of the splice at 5 ends of the intron 5-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction two frame shifts and a mutation of the splice site-ref1) is able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggest that the interaction two frameshifts and a splice site mutation leads to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction Display of the SNU246 gene in yeast-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction Display of the SNU246 gene in yeast-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction disorganization of the SNU246 gene in the yeast-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1) was able to lead to transcriptional suppression C2+e.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction loss of the TreR function-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">loss of the TreR function</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction the different amino terminals-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">the different amino terminals</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction the distinct termini amino acid-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction the mutation of the splice at 5 ends of the intron 5-ref1 could lead to transcriptional suppression C2+e.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>In addition, experiments with an antisense DNA expression vector cDNA introduced in cultivated cells suggested that the interaction the mutation of the splice at 5 ends of the intron 5-ref1 had led to transcriptional suppression C2+e.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction a complex mutation of the coupling site leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction loss of the TreR function leads to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>In addition, experiments with an antisense cDNA DNA expression vector introduced in cultivated cells suggest that the interaction the distinct termini amino acid leads to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14-ref1 is able to lead to transcriptional suppression a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction growth of Escherichia coli in the presence of nitrate or nitrite-ref1 is able to lead to transcriptional suppression a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction the 5-end mutation of the intron 5-ref1 is able to lead to transcriptional suppression abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>In addition, experiments with antisense-ref cDNA expression vector introduced in cultivated cells suggest that the interaction the different amino terminals-ref1 is able to lead to transcriptional suppression the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>In inactivation of the MEF2C gene homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>In inactivation of the MEF2C gene homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>In inactivation of the MEF2C gene homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>In inactivation of the MEF2C gene homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>In loss of the TreR function homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>In loss of the TreR function homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>In the 5-end mutation of the intron 5 homologous part of the genes, GBP does not have an exon due to this, which inactivates the pulse segmentation event and leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>In the distinct termini amino acid homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>In this homologous part of genes, GBP lacks an exon due to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>In this homologous part of genes, GBP lacks an exon due to G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>In this homologous part of genes, GBP lacks an exon due to a complex coupling site mutation, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>In this homologous part of genes, GBP lacks an exon due to a complex mutation of the coupling site, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>In this homologous part of genes, GBP lacks an exon due to disorganization of the SNU246 gene in the yeast, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>In this homologous part of genes, GBP lacks an exon due to growth of Escherichia coli in the presence of nitrate or nitrite, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>In this homologous part of genes, GBP lacks an exon due to the different amino terminals, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>In this homologous part of genes, GBP lacks an exon due to the distinct termini amino acid, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>In this homologous part of genes, GPB does not have an exon due to 7 mutations without sense, 2 mutations, which inactivates the pulse event of the 5th and may lead to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>In this homologous part of genes, GPB does not have an exon due to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the pulse event of the 5th and may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>In this homologous part of genes, GPB does not have an exon due to a complex mutation of the coupling site, which inactivates the pulse event of the 5th and may lead to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>In this homologous part of genes, GPB does not have an exon due to growth of Escherichia coli in the presence of nitrate or nitrite, which inactivates the pulse event of the 5th and may lead to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>In this homologous part of genes, GPB does not have an exon due to growth of Escherichia coli in the presence of nitrate or nitrite, which inactivates the pulse event of the 5th and may lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>In this homologous part of genes, GPB does not have an exon due to inactivation of the MEF2C gene, which inactivates the pulse event of the 5th and may lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>In this homologous part of genes, GPB does not have an exon due to loss of the TreR function, which inactivates the pulse event of the 5th and may lead to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>In this homologous part of genes, GPB does not have an exon due to this mutation at 5 ends of the intron 5, which inactivates the pulse event of the 5th and may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>In this homologous part of the genes, GBP does not have an exon due to 7 mutations without sense, 2 mutations, which inactivates the pulse segmentation event and leads to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>In this homologous part of the genes, GBP does not have an exon due to 7 senseless mutations, 2 mutations, which inactivates the pulse segmentation event and leads to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>In this homologous part of the genes, GBP does not have an exon due to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14, which inactivates the pulse segmentation event and leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>In this homologous part of the genes, GBP does not have an exon due to a complex coupling site mutation, which inactivates the pulse segmentation event and leads to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>In this homologous part of the genes, GBP does not have an exon due to disorganization of the SNU246 gene in the yeast, which inactivates the pulse segmentation event and leads to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>In this homologous part of the genes, GBP does not have an exon due to inactivation of the MEF2C gene, which inactivates the pulse segmentation event and leads to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>In this homologous part of the genes, GBP does not have an exon due to loss of the TreR function, which inactivates the pulse segmentation event and leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>In this homologous part of the genes, GBP does not have an exon due to the different amino acid terminals, which inactivates the pulse segmentation event and leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>In this homologous part of the genes, GBP does not have an exon due to the different amino terminals, which inactivates the pulse segmentation event and leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>In this mutation at 5 ends of the intron 5 homologous part of genes, GBP lacks an exon due to this, which inactivates the fifth segmentation event of the application of the cleavage and is able to lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>In two frame shifts and a mutation of the splice site homologous part of genes, GPB does not have an exon due to this, which inactivates the pulse event of the 5th and may lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>The 7 absent mutations, 2 mutations led to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>The Display of the SNU246 gene in yeast led to the a defect of in vivo splicing, indicating that the protein is essential for splicing appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>The G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>The G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to the a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>The G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to the a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>The G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 led to the a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>The G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive charge in a highly conserved transmembrane domain (R496S) appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>The G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 led to the a substitution of a positive charge in a highly conserved transmembrane domain (R496S) appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>The a complex coupling site mutation leads to the an altered ARNJ1 resulting in a premature stop codon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>The a complex mutation of the coupling site will lead to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>The a point mutation at the application site of the third intron leads to the ligation of the second to the fourth intron appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>The a point mutation at the application site of the third intron led to the ligation of the second to the fourth intron appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>The a point mutation at the splicing 5 site of the third intron led to the ligation of the second to the fourth exon appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>The a point mutation at the splicing 5 site of the third intron will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>The disorganization of the SNU246 gene in the yeast led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>The growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>The identified mutations include: G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>The identified mutations include: the distinct termini amino acid leading to A1 (proteins of OA1 vegetated; removal of a threonine codon at position 290; and four mutations of the opposite direction, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>The inactivation of the MEF2C gene can lead to the morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>The inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>The inactivation of the MEF2C gene led to the morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>The inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>The loss of the TreR function leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>The loss of the TreR function leads to the derepression of treB appears to be one of the causes of X-linked recessive adreoleukodrophite.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>The loss of the TreR function led to the derepression of the treB appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>The loss of the TreR function led to the derepression of treB appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>The loss of the TreR function will lead to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>The mutations identified include: G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S), two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>The mutations identified include: G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S), two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>The mutations identified include: G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive load in a highly conserved transmembrane domain (R496S), two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>The mutations identified include: a complex coupling site mutation leading to an altered ARNJ1 resulting in a premature stop codon, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>The mutations identified include: a complex coupling site mutation that led to an altered ARNJ1 resulting in a premature stop codon, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>The mutations identified include: a complex mutation of the coupling site leading to an abnormal JNA, resulting in a premature arrest codon, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>The mutations identified include: growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>The mutations identified include: inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>The mutations identified include: inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>The mutations identified include: inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>The mutations identified include: inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>The mutations identified include: the 5-end mutation of the intron 5 that led to abnormal portion in exon 5 and exon 6, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>The mutations identified include: the mutation of the splice at 5 ends of the intron 5 leading to the abnormal splice in exon 5 and exon 6, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>The mutations identified include: the mutation of the splice at 5 ends of the intron 5 that led to the splice in exon 5 and exon 6, two of them involving amino acids within the transmembrane putative domains.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>The mutations identified include: this mutation at 5 ends of the intron 5 leading to abnormal portion in exon 5 and exon 6, two of them involving amino acids located in putative transmembranous domains.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>The mutations identified include: this mutation at 5 ends of the intron 5 that led to abnormal portion in exon 5 and exon 6, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>The mutations identified include: two frameshifts and a splice site mutation that led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, two of them involving amino acids located in putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>The the 5-end mutation of the intron 5 will lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>The the distinct termini amino acid led to the the direction of individual VDAC isoforms to different cellular compartments appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>The the mutation of the splice at 5 ends of the intron 5 led to the the abnormal splice in exon 5 and exon 6 appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>The the mutation of the splice at 5 ends of the intron 5 led to the the splice in exon 5 and exon 6 appears to be one of the causes of the X-linked recessive adreolechodrophy.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to 7 absent mutations, 2 mutations.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to 7 mutations without sense, 2 mutations.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, is able to lead to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, may lead to loss of the TreR function.</text>
                    <arg n="0">loss of the TreR function</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to 7 absent mutations, 2 mutations.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to a complex coupling site mutation.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to disorganization of the SNU246 gene in the yeast.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>The transduction of the MarA region from a sea strain, but not from a wild strain, will lead to the mutation of the splice at 5 ends of the intron 5.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to 7 mutations without sense, 2 mutations.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to a complex coupling site mutation.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>The transduction of the SeaA region from a sea strain, but not from a wild type, led to two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to disorganization of the SNU246 gene in the yeast.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>The transduction of the sea region from a sea strain, but not from a wild strain, leads to the different amino acid terminals.</text>
                    <arg n="0">the different amino acid terminals</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to growth of Escherichia coli in the presence of nitrate or nitrite.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to the different amino acid terminals.</text>
                    <arg n="0">the different amino acid terminals</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>The transduction of the sea regionA of a sea strain, but not a wild strain, is able to lead to this mutation at 5 ends of the intron 5.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>The two frame shifts and a mutation of the splice site can lead to the shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations appears to be one of the causes of the X-linked recessive adreoleukodropy.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>The two frame shifts and a mutation of the splice site leads to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>The two frameshifts and a splice site mutation led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>The two frameshifts and a splice site mutation will lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>These data suggest that 7 senseless mutations, 2 mutations led to frame shift that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>These data suggest that G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>These data suggest that G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>These data suggest that G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>These data suggest that G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 may lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>These data suggest that G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 was able to lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S) that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>These data suggest that a complex mutation of the coupling site may lead to an abnormal JNA, resulting in a premature arrest codon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>These data suggest that a complex mutation of the coupling site was able to lead to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>These data suggest that growth of Escherichia coli in the presence of nitrate or nitrite was able to lead to a 45% expression decrease that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>These data suggest that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>These data suggest that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>These data suggest that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>These data suggest that inactivation of the MEF2C gene may lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>These data suggest that inactivation of the MEF2C gene was able to lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>These data suggest that inactivation of the MEF2C gene was able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>These data suggest that loss of the TreR function led to derepression of treB that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>These data suggest that loss of the TreR function may lead to derepression of treB that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>These data suggest that the 5-end mutation of the intron 5 may lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>These data suggest that the different amino terminals led to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>These data suggest that the distinct termini amino acid may lead to the direction of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>These data suggest that the mutation of the splice at 5 ends of the intron 5 led to the abnormal splice in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>These data suggest that the mutation of the splice at 5 ends of the intron 5 led to the splice in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>These data suggest that the mutation of the splice at 5 ends of the intron 5 may lead to the splice in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>These data suggest that two frameshifts and a splice site mutation was able to lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>This DNA of patients contains G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 allele that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>This DNA of patients contains G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 allele that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>This DNA of patients contains G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>This DNA of patients contains a complex coupling site mutation allele that can lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>This DNA of patients contains a complex mutation of the coupling site that led to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>This DNA of patients contains disorganization of the SNU246 gene in the yeast that led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>This DNA of patients contains inactivation of the MEF2C gene allele that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>This DNA of patients contains inactivation of the MEF2C gene allele that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>This DNA of patients contains inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>This DNA of patients contains loss of the TreR function allele that can lead to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>This DNA of patients contains the different amino acid terminals that led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>This DNA of patients contains the different amino terminals that led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>This DNA of patients contains the mutation of the splice at 5 ends of the intron 5 allele that can lead to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>This base pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations that led to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>This base pair G:C is also the strongest determinant in G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 that has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>This base pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 that has led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>This base pair G:C is also the strongest determinant in G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive load in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>This base pair G:C is also the strongest determinant in a complex coupling site mutation that has led to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>This base pair G:C is also the strongest determinant in a complex coupling site mutation that led to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>This base pair G:C is also the strongest determinant in a complex mutation of the coupling site leads to an abnormal JAG1 mRNA, resulting in a premature halting codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>This base pair G:C is also the strongest determinant in a complex mutation of the coupling site leads to an altered JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>This base pair G:C is also the strongest determinant in a complex mutation of the coupling site that led to an altered JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>This base pair G:C is also the strongest determinant in a point mutation at the application site of the third intron leading to ligation of the second to the fourth intron (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>This base pair G:C is also the strongest determinant in disorganization of the SNU246 gene in the yeast leading to in vivo splicing defect, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>This base pair G:C is also the strongest determinant in growth of Escherichia coli in the presence of nitrate or nitrite leads to a 45% expression decrease (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>This base pair G:C is also the strongest determinant in growth of Escherichia coli in the presence of nitrate or nitrite that has led to a 45% expression decrease (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene that has led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene that has led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>This base pair G:C is also the strongest determinant in inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>This base pair G:C is also the strongest determinant in loss of the TreR function leading to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>This base pair G:C is also the strongest determinant in loss of the TreR function that has led to derepression of the treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>This base pair G:C is also the strongest determinant in the different amino terminals that has led to the orientation of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>This base pair G:C is also the strongest determinant in the distinct termini amino acid that led to the direction of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>This base pair G:C is also the strongest determinant in the mutation of the splice at 5 ends of the intron 5 leading to the splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>This base pair G:C is also the strongest determinant in the mutation of the splice at 5 ends of the intron 5 leads to the abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>This base pair G:C is also the strongest determinant in two frame shifts and a mutation of the splice site that led to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>This basic pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations leading to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>This basic pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations that leads to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>This basic pair G:C is also the strongest determinant in 7 absent mutations, 2 mutations that led to shifting in frames (Lagrange et al., 1998).</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>This basic pair G:C is also the strongest determinant in Display of the SNU246 gene in yeast that led to a defect of in vivo splicing, indicating that the protein is essential for splicing (Lagrange et al., 1998).</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>This basic pair G:C is also the strongest determinant in G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>This basic pair G:C is also the strongest determinant in G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>This basic pair G:C is also the strongest determinant in G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S) (Lagrange et al., 1998).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>This basic pair G:C is also the strongest determinant in a point mutation at the splicing 5 site of the third intron that led to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>This basic pair G:C is also the strongest determinant in inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>This basic pair G:C is also the strongest determinant in the 5-end mutation of the intron 5 that led to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>This basic pair G:C is also the strongest determinant in the distinct termini amino acid that leads to the direction of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>This basic pair G:C is also the strongest determinant in the distinct termini amino acid that led to the direction of individual VDAC isoforms to different cellular compartments (Lagrange et al., 1998).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>This basic pair G:C is also the strongest determinant in the mutation of the splice at 5 ends of the intron 5 that led to the abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>This data suggests that 7 absent mutations, 2 mutations can lead to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>This data suggests that 7 absent mutations, 2 mutations has led to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>This data suggests that 7 absent mutations, 2 mutations will lead to shifting in frames that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>This data suggests that 7 senseless mutations, 2 mutations has led to frame shift that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>This data suggests that 7 senseless mutations, 2 mutations led to frame shift that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>This data suggests that G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>This data suggests that G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>This data suggests that a complex coupling site mutation can lead to an altered ARNJ1 resulting in a premature stop codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>This data suggests that a complex mutation of the coupling site led to an altered JNA, resulting in a premature arrest codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>This data suggests that a complex mutation of the coupling site was able to lead to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>This data suggests that a point mutation at the application site of the third intron can lead to ligation of the second to the fourth intron that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>This data suggests that a point mutation at the application site of the third intron led to ligation of the second to the fourth intron working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>This data suggests that a point mutation at the application site of the third intron was able to lead to ligation of the second to the fourth intron that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>This data suggests that a point mutation at the splicing 5 site of the third intron can lead to ligation of the second to the fourth exon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>This data suggests that a point mutation at the splicing 5 site of the third intron led to ligation of the second to the fourth exon working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>This data suggests that disorganization of the SNU246 gene in the yeast led to in vivo splicing defect, indicating that the protein is essential for splicing that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>This data suggests that disorganization of the SNU246 gene in the yeast led to in vivo splicing defect, indicating that the protein is essential for splicing working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>This data suggests that disorganization of the SNU246 gene in the yeast was able to lead to in vivo splicing defect, indicating that the protein is essential for splicing that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>This data suggests that growth of Escherichia coli in the presence of nitrate or nitrite has led to a 45% expression decrease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>This data suggests that growth of Escherichia coli in the presence of nitrate or nitrite will lead to a 45% expression decrease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>This data suggests that inactivation of the MEF2C gene has led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>This data suggests that inactivation of the MEF2C gene has led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>This data suggests that inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>This data suggests that inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>This data suggests that the 5-end mutation of the intron 5 has led to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>This data suggests that the different amino acid terminals has led to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>This data suggests that the distinct termini amino acid led to the direction of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>This data suggests that the mutation of the splice at 5 ends of the intron 5 will lead to the splice in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>This data suggests that two frame shifts and a mutation of the splice site can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>This data suggests that two frameshifts and a splice site mutation was able to lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>This patient DNA contains Display of the SNU246 gene in yeast which leads to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>This patient DNA contains G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14 that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>This patient DNA contains G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>This patient DNA contains G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>This patient DNA contains G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 leads to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>This patient DNA contains G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14 that can lead to a substitution of a positive load in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>This patient DNA contains a complex mutation of the coupling site which leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>This patient DNA contains a point mutation at the application site of the third intron which leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>This patient DNA contains disorganization of the SNU246 gene in the yeast leads to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>This patient DNA contains disorganization of the SNU246 gene in the yeast that can lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>This patient DNA contains growth of Escherichia coli in the presence of nitrate or nitrite that can lead to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>This patient DNA contains growth of Escherichia coli in the presence of nitrate or nitrite which leads to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>This patient DNA contains inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>This patient DNA contains inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>This patient DNA contains inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>This patient DNA contains inactivation of the MEF2C gene that can lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>This patient DNA contains inactivation of the MEF2C gene that can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>This patient DNA contains inactivation of the MEF2C gene which leads to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>This patient DNA contains inactivation of the MEF2C gene which leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>This patient DNA contains loss of the TreR function leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>This patient DNA contains loss of the TreR function which leads to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>This patient DNA contains the different amino terminals leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>This patient DNA contains the mutation of the splice at 5 ends of the intron 5 that can lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>This patient DNA contains this mutation at 5 ends of the intron 5 that can lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>This patients DNA contains G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>This patients DNA contains G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>This patients DNA contains growth of Escherichia coli in the presence of nitrate or nitrite leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>This patients DNA contains inactivation of the MEF2C gene leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>This patients DNA contains the different amino terminals leads to A1 (an insertion of 4 bp into mRNA and a change in inactive framework in the C----A-B.</text>
                    <arg n="0">the different amino terminals</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>This was caused by 7 absent mutations, 2 mutations that led to shifting in frames.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>This was caused by 7 mutations without sense, 2 mutations which has led to table transfer.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>This was caused by 7 senseless mutations, 2 mutations that led to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>This was caused by 7 senseless mutations, 2 mutations which has led to frame shift.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                    <arg n="1">frame shift</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>This was caused by Display of the SNU246 gene in yeast that may lead to a defect of in vivo splicing, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Display of the SNU246 gene in yeast</arg>
                    <arg n="1">a defect of in vivo splicing, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that can lead to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a positive replacement of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 that led to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>This was caused by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14 which led to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>This was caused by G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14 leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>This was caused by G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 that leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>This was caused by G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14 which leading to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>This was caused by G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>This was caused by G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14 which leading to a substitution of a positive charge in a highly conserved transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>This was caused by a complex mutation of the coupling site that leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>This was caused by a point mutation at the application site of the third intron leading to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>This was caused by a point mutation at the application site of the third intron which led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>This was caused by a point mutation at the splicing 5 site of the third intron which led to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>This was caused by disorganization of the SNU246 gene in the yeast which leading to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>This was caused by disorganization of the SNU246 gene in the yeast which led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that led to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>This was caused by growth of Escherichia coli in the presence of nitrate or nitrite that may lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>This was caused by inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>This was caused by inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>This was caused by inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>This was caused by inactivation of the MEF2C gene that can lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>This was caused by inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>This was caused by inactivation of the MEF2C gene that leads to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>This was caused by inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>This was caused by inactivation of the MEF2C gene that led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>This was caused by inactivation of the MEF2C gene that may lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>This was caused by inactivation of the MEF2C gene which led to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>This was caused by inactivation of the MEF2C gene which led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>This was caused by loss of the TreR function leads to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>This was caused by loss of the TreR function which led to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>This was caused by the 5-end mutation of the intron 5 that may lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>This was caused by the different amino acid terminals which led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>This was caused by the different amino terminals that led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>This was caused by the different amino terminals which has led to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>This was caused by the distinct termini amino acid leads to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>This was caused by this mutation at 5 ends of the intron 5 leading to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>This was caused by this mutation at 5 ends of the intron 5 which leading to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>This was caused by this mutation at 5 ends of the intron 5 which led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>This was caused by two frame shifts and a mutation of the splice site which leading to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>This was caused by two frameshifts and a splice site mutation that leads to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>This was caused by two frameshifts and a splice site mutation which led to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to a point mutation at the application site of the third intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to the 5-end mutation of the intron 5.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, can lead to the different amino acid terminals.</text>
                    <arg n="0">the different amino acid terminals</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to 7 mutations without sense, 2 mutations.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>Transduction of the MarA region from a sea strain, but not a wild-type strain, will lead to G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a consensual site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to 7 senseless mutations, 2 mutations.</text>
                    <arg n="0">7 senseless mutations, 2 mutations</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to a point mutation at the application site of the third intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>Transduction of the MarA region from a sea strain, but not of a wild type, has led to the distinct termini amino acid.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to a complex mutation of the coupling site.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>Transduction of the mara region from a sea strain, but not a wild-type strain, leads to two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>a complex coupling site mutation DNA of patients contains This allele that can lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>a complex coupling site mutation base pair G:C is also the strongest determinant in This that has led to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>a complex coupling site mutation basic pair G:C is also the strongest determinant in This leading to an altered ARNJ1 resulting in a premature stop codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>a complex coupling site mutation is able to lead an altered ARNJ1 resulting in a premature stop codon (picture 3A).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>a complex coupling site mutation is able to lead to an altered ARNJ1 resulting in a premature stop codon (figure 3A).</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>a complex coupling site mutation is able to lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>a complex coupling site mutation leads to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>a complex coupling site mutation was able to lead to an altered ARNJ1 resulting in a premature stop codon when the cells were grown in rich environments.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>a complex coupling site mutation was caused by This leads to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>a complex coupling site mutation was caused by This that can lead to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>a complex coupling site mutation was caused by This that leads to an altered ARNJ1 resulting in a premature stop codon.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>a complex mutation of the coupling site DNA of patients contains This allele that can lead to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>a complex mutation of the coupling site base pair G:C is also the strongest determinant in This leading to an abnormal JAG1 mRNA, resulting in a premature halting codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>a complex mutation of the coupling site base pair G:C is also the strongest determinant in This leads to an abnormal JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>a complex mutation of the coupling site base pair G:C is also the strongest determinant in This that led to an abnormal JAG1 mRNA, resulting in a premature halting codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>a complex mutation of the coupling site basic pair G:C is also the strongest determinant in This that led to an altered JNA, resulting in a premature arrest codon (Lagrange et al., 1998).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>a complex mutation of the coupling site can lead to an abnormal JAG1 mRNA, resulting in a premature halting codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>a complex mutation of the coupling site data suggests that This can lead to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>a complex mutation of the coupling site data suggests that This has led to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>a complex mutation of the coupling site data suggests that This led to an abnormal JAG1 mRNA, resulting in a premature halting codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>a complex mutation of the coupling site data suggests that This led to an altered JNA, resulting in a premature arrest codon that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>a complex mutation of the coupling site is able to lead an abnormal JAG1 mRNA, resulting in a premature halting codon (picture 3A).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>a complex mutation of the coupling site leading to an altered JNA, resulting in a premature arrest codon, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>a complex mutation of the coupling site leading to an altered JNA, resulting in a premature arrest codon, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>a complex mutation of the coupling site leads to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>a complex mutation of the coupling site led an altered JNA, resulting in a premature arrest codon to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>a complex mutation of the coupling site led to an abnormal JAG1 mRNA, resulting in a premature halting codon (figure 3A).</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>a complex mutation of the coupling site led to an abnormal JAG1 mRNA, resulting in a premature halting codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature halting codon</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>a complex mutation of the coupling site was caused by This leads to an altered JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>a complex mutation of the coupling site was caused by This that leads to an abnormal JNA, resulting in a premature arrest codon.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an abnormal JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>a complex mutation of the coupling site, in turn, is leading to an altered JNA, resulting in a premature arrest codon regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a complex mutation of the coupling site</arg>
                    <arg n="1">an altered JNA, resulting in a premature arrest codon</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>a point mutation at the application site of the third intron basic pair G:C is also the strongest determinant in This that leads to ligation of the second to the fourth intron (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>a point mutation at the application site of the third intron leads to ligation of the second to the fourth intron coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>a point mutation at the application site of the third intron led to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>a point mutation at the application site of the third intron may lead to ligation of the second to the fourth intron coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>a point mutation at the application site of the third intron patient DNA contains This leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>a point mutation at the application site of the third intron patient DNA contains This which leads to ligation of the second to the fourth intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>a point mutation at the splicing 5 site of the third intron DNA of patients contains This allele that can lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>a point mutation at the splicing 5 site of the third intron basic pair G:C is also the strongest determinant in This leading to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>a point mutation at the splicing 5 site of the third intron basic pair G:C is also the strongest determinant in This that leads to ligation of the second to the fourth exon (Lagrange et al., 1998).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>a point mutation at the splicing 5 site of the third intron is able to lead ligation of the second to the fourth exon (picture 3A).</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>a point mutation at the splicing 5 site of the third intron will lead to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>a point mutation at the splicing 5 site of the third intron, in turn, is leading to ligation of the second to the fourth exon regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) is led to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S) was led to G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of splices at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>a substitution of a positive charge in a highly conserved transmembrane domain (R496S) was led by G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>a substitution of a positive charge in a highly conserved transmembrane domain (R496S) was led to G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affected a consensus site of the splice at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive charge in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>a substitution of a positive load in a highly conserved transmembrane domain (R496S) is led by G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14.</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T at exon 14</arg>
                    <arg n="1">a substitution of a positive load in a highly conserved transmembrane domain (R496S)</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>abnormal portion in exon 5 and exon 6 was led to this mutation at 5 ends of the intron 5.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>an altered ARNJ1 resulting in a premature stop codon is led to a complex coupling site mutation.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>an altered ARNJ1 resulting in a premature stop codon was led to a complex coupling site mutation.</text>
                    <arg n="0">a complex coupling site mutation</arg>
                    <arg n="1">an altered ARNJ1 resulting in a premature stop codon</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>disorganization of the SNU246 gene in the yeast DNA of patients contains This allele that can lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>disorganization of the SNU246 gene in the yeast can lead to in vivo splicing defect, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>disorganization of the SNU246 gene in the yeast can lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>disorganization of the SNU246 gene in the yeast data suggests that This led to in vivo splicing defect, indicating that the protein is essential for splicing that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>disorganization of the SNU246 gene in the yeast has led in in vivo splicing defect, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>disorganization of the SNU246 gene in the yeast leading to in vivo splicing defect, indicating that the protein is essential for splicing, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>disorganization of the SNU246 gene in the yeast led to in vivo splicing defect, indicating that the protein is essential for splicing (figuration 3A).</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>disorganization of the SNU246 gene in the yeast patient DNA contains This that can lead to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>disorganization of the SNU246 gene in the yeast was caused by This which has led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>disorganization of the SNU246 gene in the yeast was caused by This which led to in vivo splicing defect, indicating that the protein is essential for splicing.</text>
                    <arg n="0">disorganization of the SNU246 gene in the yeast</arg>
                    <arg n="1">in vivo splicing defect, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite DNA of patients contains This allele that can lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite DNA of patients contains This that led to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite base pair G:C is also the strongest determinant in This leads to a 45% decrease in expression (Lagrange et al., 1998).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite data suggests that This will lead to a 45% expression decrease that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite has led in a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite is able to lead to a 45% decrease in expression (figure 3A).</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite is able to lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite is leading to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was caused by This leads to a 45% decrease in expression.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% decrease in expression</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was caused by This leads to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite was caused by This that can lead to a 45% expression decrease.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>growth of Escherichia coli in the presence of nitrate or nitrite, in turn, is leading to a 45% expression decrease regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">growth of Escherichia coli in the presence of nitrate or nitrite</arg>
                    <arg n="1">a 45% expression decrease</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>inactivation of the MEF2C gene DNA of patients contains This allele that can lead to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>inactivation of the MEF2C gene DNA of patients contains This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>inactivation of the MEF2C gene DNA of patients contains This that led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This leads to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This that has led to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>inactivation of the MEF2C gene base pair G:C is also the strongest determinant in This that led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This that leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>inactivation of the MEF2C gene basic pair G:C is also the strongest determinant in This that led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic (Lagrange et al., 1998).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>inactivation of the MEF2C gene can lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>inactivation of the MEF2C gene data suggests that This has led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>inactivation of the MEF2C gene data suggests that This led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>inactivation of the MEF2C gene data suggests that This led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>inactivation of the MEF2C gene data suggests that This was able to lead to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>inactivation of the MEF2C gene data suggests that This was able to lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>inactivation of the MEF2C gene data suggests that This will lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>inactivation of the MEF2C gene is able to lead morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (picture 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>inactivation of the MEF2C gene is able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>inactivation of the MEF2C gene is able to lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 (figure 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>inactivation of the MEF2C gene is leading to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>inactivation of the MEF2C gene is leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>inactivation of the MEF2C gene leading to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>inactivation of the MEF2C gene leads to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>inactivation of the MEF2C gene led morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo (figuration 3A).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>inactivation of the MEF2C gene led to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>inactivation of the MEF2C gene patient DNA contains This that can lead to morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>inactivation of the MEF2C gene was able to lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo when the cells were grown in rich environments.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>inactivation of the MEF2C gene was caused by This leading to morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>inactivation of the MEF2C gene was caused by This leading to morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>inactivation of the MEF2C gene was caused by This leads to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>inactivation of the MEF2C gene was caused by This that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>inactivation of the MEF2C gene was caused by This that can lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>inactivation of the MEF2C gene was caused by This that can lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>inactivation of the MEF2C gene was caused by This that leads to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>inactivation of the MEF2C gene was caused by This that led to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>inactivation of the MEF2C gene was caused by This that may lead to morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>inactivation of the MEF2C gene was caused by This which led to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>inactivation of the MEF2C gene was caused by This which led to morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryonic</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>inactivation of the MEF2C gene will lead to morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality by day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>ligation of the second to the fourth exon was led to a point mutation at the splicing 5 site of the third intron.</text>
                    <arg n="0">a point mutation at the splicing 5 site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>ligation of the second to the fourth intron was led to a point mutation at the application site of the third intron.</text>
                    <arg n="0">a point mutation at the application site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth intron</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>loss of the TreR function base pair G:C is also the strongest determinant in This leading to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>loss of the TreR function base pair G:C is also the strongest determinant in This that led to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>loss of the TreR function basic pair G:C is also the strongest determinant in This that leads to derepression of treB (Lagrange et al., 1998).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>loss of the TreR function can lead to derepression of treB, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>loss of the TreR function data suggests that This can lead to derepression of the treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>loss of the TreR function data suggests that This has led to derepression of treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>loss of the TreR function data suggests that This led to derepression of treB that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>loss of the TreR function is able to lead derepression of treB (picture 3A).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>loss of the TreR function led derepression of treB to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>loss of the TreR function led to derepression of treB, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>loss of the TreR function was caused by This that can lead to derepression of treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of treB</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>loss of the TreR function was caused by This which led to derepression of the treB.</text>
                    <arg n="0">loss of the TreR function</arg>
                    <arg n="1">derepression of the treB</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5 is led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5 is led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and morbidity per day embryonic 9.5</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo is led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality at day 9.5 embryo</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day is led to inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day was led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities and mortality on the 9.5 embryonic day</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos was led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and death on the 9.5 embryos</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 is led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5 was led by inactivation of the MEF2C gene.</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">morphogenetic cardiac defects, vascular abnormalities, and lethality per embryonic day 9.5</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>shifting in frames was led to 7 absent mutations, 2 mutations.</text>
                    <arg n="0">7 absent mutations, 2 mutations</arg>
                    <arg n="1">shifting in frames</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations was led to two frame shifts and a mutation of the splice site.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>table transfer was led by 7 mutations without sense, 2 mutations.</text>
                    <arg n="0">7 mutations without sense, 2 mutations</arg>
                    <arg n="1">table transfer</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>the 5-end mutation of the intron 5 data suggests that This was able to lead to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>the 5-end mutation of the intron 5 leads to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>the 5-end mutation of the intron 5 led abnormal portion in exon 5 and exon 6 to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>the 5-end mutation of the intron 5 led to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>the 5-end mutation of the intron 5 was caused by This leading to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">the 5-end mutation of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>the different amino acid terminals can lead to the orientation of individual VDAC isoforms to different cellular compartments (figuration 3A).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>the different amino acid terminals is able to lead the orientation of individual VDAC isoforms to different cellular compartments (picture 3A).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>the different amino acid terminals is able to lead to the orientation of individual VDAC isoforms to different cellular compartments (figure 3A).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>the different amino acid terminals leading to the orientation of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>the different amino acid terminals was caused by This leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino acid terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>the different amino terminals data suggests that This can lead to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>the different amino terminals data suggests that This has led to the orientation of individual VDAC isoforms to different cellular compartments that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>the different amino terminals is able to lead to the orientation of individual VDAC isoforms to different cellular compartments (figure 3A).</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>the different amino terminals led to the orientation of individual VDAC isoforms to different cellular compartments (figure 3A).</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>the different amino terminals was caused by This leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>the different amino terminals was caused by This that leads to the orientation of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the different amino terminals</arg>
                    <arg n="1">the orientation of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>the distinct termini amino acid data suggests that This led to the direction of individual VDAC isoforms to different cellular compartments working to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>the distinct termini amino acid has led in the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>the distinct termini amino acid leads to the direction of individual VDAC isoforms to different cellular compartments coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>the distinct termini amino acid leads to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>the distinct termini amino acid led to the direction of individual VDAC isoforms to different cellular compartments, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>the distinct termini amino acid was caused by This which has led to the direction of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>the distinct termini amino acid will lead to the direction of individual VDAC isoforms to different cellular compartments coding an enzyme IITre of PTS for trehalose and the TreC coding enzyme TreC, cytoplasmic trehalose-6-phosphate-hydroxylase.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>the distinct termini amino acid, in turn, is leading to the direction of individual VDAC isoforms to different cellular compartments regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">the distinct termini amino acid</arg>
                    <arg n="1">the direction of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>the mutation of the splice at 5 ends of the intron 5 base pair G:C is also the strongest determinant in This leads to the splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>the mutation of the splice at 5 ends of the intron 5 base pair G:C is also the strongest determinant in This that led to the abnormal splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>the mutation of the splice at 5 ends of the intron 5 basic pair G:C is also the strongest determinant in This that led to the splice in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>the mutation of the splice at 5 ends of the intron 5 is able to lead to the abnormal splice in exon 5 and exon 6 (figure 3A).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>the mutation of the splice at 5 ends of the intron 5 is leading to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>the mutation of the splice at 5 ends of the intron 5 led the abnormal splice in exon 5 and exon 6 to codify a PTS enzyme IITre for trealose and to codify treC TreC, trealose-6-phosphate-hydroxylase cytoplasmic.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>the mutation of the splice at 5 ends of the intron 5 led to the splice in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>the mutation of the splice at 5 ends of the intron 5 may lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>the mutation of the splice at 5 ends of the intron 5 was able to lead to the abnormal splice in exon 5 and exon 6 when the cells were grown in rich environments.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This that can lead to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This that leads to the abnormal splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>the mutation of the splice at 5 ends of the intron 5 was caused by This which has led to the splice in exon 5 and exon 6.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>the mutation of the splice at 5 ends of the intron 5, in turn, is leading to the abnormal splice in exon 5 and exon 6 regardless of the DNA binding activity of MEF2.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>the splice in exon 5 and exon 6 is led by the mutation of the splice at 5 ends of the intron 5.</text>
                    <arg n="0">the mutation of the splice at 5 ends of the intron 5</arg>
                    <arg n="1">the splice in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>this mutation at 5 ends of the intron 5 DNA of patients contains This that led to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>this mutation at 5 ends of the intron 5 basic pair G:C is also the strongest determinant in This leading to abnormal portion in exon 5 and exon 6 (Lagrange et al., 1998).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>this mutation at 5 ends of the intron 5 data suggests that This has led to abnormal portion in exon 5 and exon 6 that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>this mutation at 5 ends of the intron 5 is able to lead abnormal portion in exon 5 and exon 6 (picture 3A).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>this mutation at 5 ends of the intron 5 leading to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>this mutation at 5 ends of the intron 5 led to abnormal portion in exon 5 and exon 6, an atypical form of Tay-Sachs disease (gM2 variant of AB limphosidosis).</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>this mutation at 5 ends of the intron 5 patient DNA contains This that can lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>this mutation at 5 ends of the intron 5 was able to lead to abnormal portion in exon 5 and exon 6 when the cells were grown in rich environments.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>this mutation at 5 ends of the intron 5 will lead to abnormal portion in exon 5 and exon 6.</text>
                    <arg n="0">this mutation at 5 ends of the intron 5</arg>
                    <arg n="1">abnormal portion in exon 5 and exon 6</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>two frame shifts and a mutation of the splice site DNA of patients contains This allele that can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>two frame shifts and a mutation of the splice site can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations, an atypical form of Tay-Sachs disease (gM2 variant of limphosis AB).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>two frame shifts and a mutation of the splice site data suggests that This can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>two frame shifts and a mutation of the splice site data suggests that This will lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations that works to stimulate phosphorylation and AchRs grouping.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>two frame shifts and a mutation of the splice site has led in shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>two frame shifts and a mutation of the splice site may lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations (figure 3A).</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>two frame shifts and a mutation of the splice site patient DNA contains This leads to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>two frame shifts and a mutation of the splice site patient DNA contains This that can lead to shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations.</text>
                    <arg n="0">two frame shifts and a mutation of the splice site</arg>
                    <arg n="1">shortened OA1 proteins; removal of a threonine codon at position 290; and four opposite-sense mutations</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>two frameshifts and a splice site mutation base pair G:C is also the strongest determinant in This leads to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations (Lagrange et al., 1998).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>two frameshifts and a splice site mutation is able to lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>two frameshifts and a splice site mutation is leading to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>two frameshifts and a splice site mutation leading to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations, an atypical form of Tay-Sachs disease (gM2 variant AB lymphosidosis).</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>two frameshifts and a splice site mutation leading to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>two frameshifts and a splice site mutation may lead to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations coding an enzyme IITre of PTS for trealose and the TreC coding enzyme TreC, cytoplasmic trealose-6-phosphate-hydroxylase.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>two frameshifts and a splice site mutation was caused by This that leads to truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated proteins of OA1; a deletion of a threonine codon at position 290; and four absent mutations</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
